Welcome to CureTech
CureTech Ltd. is a biotechnology company developing novel, broad-spectrum, immune modulating products for the treatment and control of cancer.
Building on the broad experience of its management, we have established a well-balanced portfolio of cancer therapies with our lead humanized antibody product, CT-011, in Phase II clinical testing. Our products are antibodies and peptide-based vaccines designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner. An extensive portfolio of issued patents and pending patent applications worldwide protects all our products and their anticipated medical uses.